-
Mashup Score: 21Discovery suggests new strategy against follicular lymphoma - 20 hour(s) ago
A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the aggressive …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Researchers Simulate the Lifetime Treatment Burden of Follicular Lymphoma | Blood Cancers Today - 17 day(s) ago
Around two-thirds of patients with follicular lymphoma receive at least two lines of therapy, and one-third receive at least three lines during their lifetime.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Common adverse reactions to zanubrutinib observed across studies included decreased neutrophil and platelet counts.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Hot off the press! 📰 🔥 The @US_FDA has granted accelerated approval to zanubrutinib when combined with obinutuzumab for the treatment of relapsed or refractory #follicularlymphoma after two or more systemic lines of therapy. @BeiGeneGlobal Learn more: https://t.co/XW0BDNQhq9 https://t.co/GLKOSyhKS7
-
-
Mashup Score: 1Liso-Cel ‘Favorable’ Safety Profile in Second-line Follicular Lymphoma | Blood Cancers Today - 1 month(s) ago
At a median follow-up of 18.1 months, the ORR and CR rates were both 95.7% following liso-cel treatment.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Researchers Simulate the Lifetime Treatment Burden of Follicular Lymphoma | Blood Cancers Today - 2 month(s) ago
Around two-thirds of patients with follicular lymphoma receive at least two lines of therapy, and one-third receive at least three lines during their lifetime.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor - 5 month(s) ago
Key Points. Both N-motif-negative and -positive tumor cells can be selected and expanded during tumor evolution.N-motif-negative tumor cells upregulate metaboli
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance - 6 month(s) ago
Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between ‘lowgrade’ (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics and outcomes are poorly understood due to lack of adequate representation in prospective trials and large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, and two comparator groups; G3AFL (n=302) and DLBCL (n=548). Composite histology with DLBCL or low-grade FL occurred in approximately half of the G3BFL cases. With a median of 5 years follow-up, the overall survival and progression-free survival of G3BFL patients was better than that of DLBCL patients (P<0.001 and P<0.001, respectively); however, G3BFL patients were younger (P<0.001) with better performance status (P<0.001), less extranodal disease (P<0.001) and more frequently had normal lactate dehydrogenase (P<0.001) at baseline. The overall and progression-free
Source: haematologica.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2VJHemOnc – The video journal of hematological oncology - 7 month(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Loretta Nastoupil just gave us a brilliant interview on liso-cel for #FollicularLymphoma and the challenges of integrating CAR-T into practice! Stay tuned for this update 👉https://t.co/O9p0vDBZp4👈 @mdandersonnews @SocietyofHemOnc #SOHO23 #SOHO2023 #Lymphoma #LYMsm #HemOnc https://t.co/PaMBdtOajQ
-
-
Mashup Score: 0First-Line Subcutaneous Rituximab May Increase PFS in Low Tumor Burden FL | ASH Clinical News | American Society of Hematology - 7 month(s) ago
Katie Robinson is a medical writer based in New York. In patients with low tumor burden follicular lymphoma (FL), subcutaneous (SC) rituximab incr eased progression-free survival (PFS) and complete response (CR) rates when used in induction followed by short maintenance compared with conventional intravenous (IV) induction without maintenance, according to a study published in the Journal of Clinical Oncology. However, high rituximab exposure during the first three months of treatment initiation was the
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Prognostic Value of PET Status for Patients With R/R Follicular Lymphoma Undergoing AutoSCT - 8 month(s) ago
Pre-autologous stem cell transplantation positron emission tomography status has strong prognostic value and may help to improve the risk stratification and selection of patients for autoSCT, according to a retrospective analysis.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to Toby A. Eyre, MD, and coauthors, the results of this analysis on patients with R/R #FollicularLymphoma "suggest that pre-SCT PET status is of clear prognostic value and may help to improve the selection of patients for autoSCT." Read more: https://t.co/vC2GS71nmy #FL https://t.co/PDQFyUPCE2
-
Discovery suggests new strategy against #follicularLymphoma @WeillCornell https://t.co/jfgi04PW4F